PEIYONG
2021-08-26
Pls like
Pfizer, BioNTech team up with Brazil’s Eurofarma to make COVID-19 vaccine for Latin America<blockquote>辉瑞、BioNTech 与巴西 Eurofarma 合作，为拉丁美洲生产 COVID-19 疫苗</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
5
3
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":810293549,"tweetId":"810293549","gmtCreate":1629978146481,"gmtModify":1631888374558,"author":{"id":3587085062023538,"idStr":"3587085062023538","authorId":3587085062023538,"authorIdStr":"3587085062023538","name":"PEIYONG","avatar":"https://static.tigerbbs.com/d91e7a49d44f9756fece9556769c80bd","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":15,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body><p>Pls like</p></body></html>","htmlText":"<html><head></head><body><p>Pls like</p></body></html>","text":"Pls like","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":5,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/810293549","repostId":1131132146,"repostType":4,"repost":{"id":"1131132146","kind":"news","pubTimestamp":1629977943,"share":"https://www.laohunote.com/m/news/1131132146?lang=zh_CN&edition=full","pubTime":"2021-08-26 19:39","market":"us","language":"en","title":"Pfizer, BioNTech team up with Brazil’s Eurofarma to make COVID-19 vaccine for Latin America<blockquote>辉瑞、BioNTech 与巴西 Eurofarma 合作，为拉丁美洲生产 COVID-19 疫苗</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1131132146","media":"Seeking Alpha","summary":"Pfizer (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) have signeda letter of intent with Brazil-based Euro","content":"<p><a href=\"https://laohu8.com/S/PFE\">Pfizer</a> (NYSE:PFE) and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (NASDAQ:BNTX) have signeda letter of intent with Brazil-based Eurofarma Laboratórios SA, to manufacture its mRNACOVID-19 vaccine, COMIRNATY for distribution within Latin America.</p><p><blockquote><a href=\"https://laohu8.com/S/PFE\">辉瑞</a>（纽约证券交易所代码：PFE）和<a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a>（纳斯达克股票代码：BNTX）已与巴西 Eurofarma Laboratórios SA 签署意向书，生产其 mRNACOVID-19 疫苗 COMIRNATY，并在拉丁美洲分销。</blockquote></p><p> Eurofarma will obtain drug product drug product from the U.S., and will perform manufacturing activities, with distribution expected to start in 2022.</p><p><blockquote>Eurofarma 将从美国获得药品 药品，并将开展生产活动，预计将于 2022 年开始分销。</blockquote></p><p> Pfizer-BioNTech's COVID-19 vaccine supply chain and manufacturing network will now span four continents and include more than 20 manufacturing facilities.</p><p><blockquote>辉瑞-BioNTech的新冠肺炎疫苗供应链和制造网络现在将横跨四大洲，包括20多个制造设施。</blockquote></p><p> At full operational capacity, the annual production is expected to exceed 100M finished doses annually. All doses will exclusively be distributed within Latin America.</p><p><blockquote>满负荷运营后，年产量预计将超过1亿剂成品剂量。所有剂量将仅在拉丁美洲分发。</blockquote></p><p> To date, Pfizer and BioNTech have shipped more than 1.3B COVID-19 vaccine doses to more than 120 countries and territories.</p><p><blockquote>迄今为止，辉瑞和BioNTech已向120多个国家和地区运送了超过1.3B剂新冠肺炎疫苗。</blockquote></p><p> Recently, Pfizer/BioNTech started rolling submission for FDA approval of booster COVID-19 shot.</p><p><blockquote>最近，辉瑞/BioNTech开始滚动提交FDA批准加强新冠肺炎疫苗。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer, BioNTech team up with Brazil’s Eurofarma to make COVID-19 vaccine for Latin America<blockquote>辉瑞、BioNTech 与巴西 Eurofarma 合作，为拉丁美洲生产 COVID-19 疫苗</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer, BioNTech team up with Brazil’s Eurofarma to make COVID-19 vaccine for Latin America<blockquote>辉瑞、BioNTech 与巴西 Eurofarma 合作，为拉丁美洲生产 COVID-19 疫苗</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2021-08-26 19:39</span>\n</p>\n</h4>\n</header>\n<article>\n<p><a href=\"https://laohu8.com/S/PFE\">Pfizer</a> (NYSE:PFE) and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (NASDAQ:BNTX) have signeda letter of intent with Brazil-based Eurofarma Laboratórios SA, to manufacture its mRNACOVID-19 vaccine, COMIRNATY for distribution within Latin America.</p><p><blockquote><a href=\"https://laohu8.com/S/PFE\">辉瑞</a>（纽约证券交易所代码：PFE）和<a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a>（纳斯达克股票代码：BNTX）已与巴西 Eurofarma Laboratórios SA 签署意向书，生产其 mRNACOVID-19 疫苗 COMIRNATY，并在拉丁美洲分销。</blockquote></p><p> Eurofarma will obtain drug product drug product from the U.S., and will perform manufacturing activities, with distribution expected to start in 2022.</p><p><blockquote>Eurofarma 将从美国获得药品 药品，并将开展生产活动，预计将于 2022 年开始分销。</blockquote></p><p> Pfizer-BioNTech's COVID-19 vaccine supply chain and manufacturing network will now span four continents and include more than 20 manufacturing facilities.</p><p><blockquote>辉瑞-BioNTech的新冠肺炎疫苗供应链和制造网络现在将横跨四大洲，包括20多个制造设施。</blockquote></p><p> At full operational capacity, the annual production is expected to exceed 100M finished doses annually. All doses will exclusively be distributed within Latin America.</p><p><blockquote>满负荷运营后，年产量预计将超过1亿剂成品剂量。所有剂量将仅在拉丁美洲分发。</blockquote></p><p> To date, Pfizer and BioNTech have shipped more than 1.3B COVID-19 vaccine doses to more than 120 countries and territories.</p><p><blockquote>迄今为止，辉瑞和BioNTech已向120多个国家和地区运送了超过1.3B剂新冠肺炎疫苗。</blockquote></p><p> Recently, Pfizer/BioNTech started rolling submission for FDA approval of booster COVID-19 shot.</p><p><blockquote>最近，辉瑞/BioNTech开始滚动提交FDA批准加强新冠肺炎疫苗。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/news/3734357-pfizer-biontech-team-up-with-brazils-eurofarma-to-make-covid-19-vaccine-for-latin-america\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BNTX":"BioNTech SE"},"source_url":"https://seekingalpha.com/news/3734357-pfizer-biontech-team-up-with-brazils-eurofarma-to-make-covid-19-vaccine-for-latin-america","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1131132146","content_text":"Pfizer (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) have signeda letter of intent with Brazil-based Eurofarma Laboratórios SA, to manufacture its mRNACOVID-19 vaccine, COMIRNATY for distribution within Latin America.\nEurofarma will obtain drug product drug product from the U.S., and will perform manufacturing activities, with distribution expected to start in 2022.\nPfizer-BioNTech's COVID-19 vaccine supply chain and manufacturing network will now span four continents and include more than 20 manufacturing facilities.\nAt full operational capacity, the annual production is expected to exceed 100M finished doses annually. All doses will exclusively be distributed within Latin America.\nTo date, Pfizer and BioNTech have shipped more than 1.3B COVID-19 vaccine doses to more than 120 countries and territories.\nRecently, Pfizer/BioNTech started rolling submission for FDA approval of booster COVID-19 shot.","news_type":1,"symbols_score_info":{"BNTX":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":645,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":7,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/810293549"}
精彩评论